ResApp Health Ltd (ASX: RAP) received a $100m takeover offer from Pfizer
ResApp Health Ltd (ASX: RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has entered into a binding scheme implementation deed with Pfizer Australia Holdings Pty Ltd (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company), under which it proposed that Pfizer Inc, will acquire 100% of the shares in ResApp Health by way of a Scheme of Arrangement for A$0.115/share in cash, representing a total equity value of approximately A$100m. ResApp CEO and managing director Tony Keating said ‘We are excited by the prospect of this acquisition by Pfizer, a leading biopharmaceutical company that shares our vision and belief that technology can help transform healthcare and improve patients’ lives.
Following the announcement, shares of ResApp Ltd traded 22.22% hjgher at $0.11/share.
Read the full story
in the Grafa app
To read the full article and more in the Grafa app, available on all app stores.
Track the trends
Get the hot tips first
Stay close to your investments
Learn to trade like a pro
Let your money entertain you
See more stories like this
48% of businesses say they will not raise prices, primarily due to the desire to...read more